Comparative Analysis of the Antiviral Activity of Various Drugs Based on 6-Fluoro-3-Hydroxy-2-Pyrazinecarboxamide (Favipiravir) Against COVID-19
Authors:
- S. Ya. LoginovaSLS. Ya. Loginova
- V. N. SchukinaVSV. N. Schukina
- S. V. SavenkoSSS. V. Savenko
- V. V. RubtsovVRV. V. Rubtsov
- S. V. BorisevichSBS. V. Borisevich
- D. L. ChizhovDCD. L. Chizhov
- G. L. RusinovGRG. L. Rusinov
- E. V. VerbitskiyEVE. V. Verbitskiy
- V. N. CharushinV. N. Charushin
- S. K. KotovskayaSKS. K. Kotovskaya
- V. L. RusinovVRV. L. Rusinov
Open Access
- 21 June 2024
- journal article
- research article
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 69 (3-4) , 21-30
Abstract
Background. The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, originated in Wuhan, China, has claimed millions of lives around the world. In this regard, the search for effective drugs, including the repurposing of existing ones, has become an urgent task. A promising treatment strategy appears to be drug disruption of viral reproduction. RNA-dependent RNA polymerase (RdRp) is the central subunit of the RNA synthesis process for all positive-strand RNA viruses and is therefore an attractive target for antiviral inhibitors.The aim of this work is an experimental study of the antiviral activity of various drugs based on 6-fluoro-3-hydroxy-2-pyrazinecarboxamide (Favipiravir) in vitro and in vivo against the SARS-CoV-2 coronavirus (COVID-19).Material and methods. The experiments were carried out on a permanent culture of African green monkey kidney cells — Vero Cl008. The effectiveness of the drugs was assessed by suppressing the reproduction of the virus in vitro. Biological activity was assessed by titration of the virus-containing suspension in Vero Cl008 cell culture by the formation of negative colonies. Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, were used in the study. The effectiveness of the drug was assessed by the coefficient of therapeutic action.Results. The results of the study revealed that the compounds FP-1 and Avifavir in the concentration range of 100–400 µg/ml almost completely suppress the reproduction of the SARS-CoV-2 virus; the CTI index for the drug FP-1 was 4, for Avifavir it was 2. The ED₅₀ value for FP-1 was 26 µg/ml, for Avifavir it was 36 µg/ml. Preparations T-705 and Coronavir revealed antiviral activity only at extremely high concentrations. The CTI was 1. During the study on Syrian golden hamsters orally infected with the SARS-CoV-2 virus, variant B, at a dose of 5×105 PFU, it was shown that the use of Avifavir and FP-1 has a high protective efficacy, while Coronavir and T-705 cause a moderate suppression of virus reproduction in the target organ. According to the complex of clinical-virological, biochemical, and hematological indicators, the disease severity index (DSI) and the therapeutic index (TI) were calculated. For the drug Avifavir, the DSI was 0.269; the TI was 71.3% with a probability of 99.9%.Conclusion. Of the studied compounds, Avifavir and FP-1 showed the highest antiviral activity.Keywords
This publication has 20 references indexed in Scilit:
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking studyLife Sciences, 2020
- Structure of the RNA-dependent RNA polymerase from COVID-19 virusScience, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nature Reviews Drug Discovery, 2020
- Favipiravir as a potential countermeasure against neglected and emerging RNA virusesAntiviral Research, 2018
- Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNAProceedings of the National Academy of Sciences, 2017
- Favipiravir: A New Medication for the Ebola Virus Disease PandemicDisaster Medicine and Public Health Preparedness, 2014
- Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research, 2013
- T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infectionsAntiviral Research, 2009